Cannabis Sativa (CBDS) Stock Price, News & Analysis

Company Overview

Cannabis Sativa, Inc., through its subsidiaries, focuses on the research, development and commercialization of pharmaceutical products derived from the cannabis plant. The company maintains a proprietary library of natural and synthetic cannabinoids and is advancing a range of preclinical and early-stage clinical programs targeting central nervous system, oncology and rare disease indications. Its efforts aim to leverage the therapeutic potential of cannabinoid molecules to address unmet medical needs.

In pursuit of its research objectives, Cannabis Sativa collaborates with academic institutions, contract research organizations and biopharmaceutical partners. The company’s strategy includes licensing and co-development agreements to support the translation of its cannabinoid formulations into clinical candidates. By combining traditional botanical extracts with novel synthetic analogs, it seeks to optimize pharmacological profiles, bioavailability and delivery mechanisms.

Headquartered in Mississauga, Ontario, Cannabis Sativa conducts operations across North America, utilizing specialized extraction and analytical platforms to ensure the quality, purity and consistency of its cannabinoid compounds. The company’s management team comprises professionals with backgrounds in pharmacology, drug development and regulatory affairs, providing the expertise needed to navigate complex clinical and commercialization pathways. As a publicly traded entity on the OTC Markets (OTCMKTS: CBDS), it aims to advance its pipeline while exploring strategic partnerships and licensing opportunities worldwide.

Key Stats

• Today's Range: $0.03 to $0.04
• 50-Day Range: $0.03 to $0.04
• 52-Week Range: $0.00 to $0.17
• Volume: 1.58 million shs
• Average Volume: 1.07 million shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CBDS Stock Analysis - Frequently Asked Questions

How have CBDS shares performed this year?

Cannabis Sativa's stock was trading at $0.0870 at the beginning of 2025. Since then, CBDS stock has decreased by 60.1% and is now trading at $0.0347.

How do I buy shares of Cannabis Sativa?

Shares of CBDS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Cannabis Sativa own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cannabis Sativa investors own include Canopy Growth (CGC), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Cara Therapeutics (CARA), 22nd Century Group (XXII) and Sangamo Therapeutics (SGMO).

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Health Information Services
• Sub-Industry: Cannabis
• Current Symbol: OTCMKTS:CBDS
• CIK: 1360442
• Web: www.cannabissativainc.com
• Phone: (702) 762-3123
• Fax: N/A
• Employees: 1
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A